655. Multiple Myeloma: Cellular Therapies: Poster III

Evolving real world uptake and patient characteristics of bispecific antibodies in Relapsed Refractory multiple myeloma Insights from a US community oncology network

Baseline PET CT in predicting CRS and survival outcomes of R R MM patients following CAR T cell therapy

Impact of renal impairment and lymphodepletion regimen on outcomes after CAR T cell therapy in relapsed refractory multiple myeloma

Subsequent primary malignancies after CAR T therapy A study from the US multiple myeloma immunotherapy consortium

Kinetics of circulating multiple myeloma cells CMMCs in patients undergoing standard of care anti BCMA chimeric antigen receptor T cell therapy for Relapsed Refractory multiple myeloma

BCMA CAR T cell expansion dynamics and toxicity after idecabtagene vicleucel and ciltacabtagene autoleucel for multiple myeloma

CD38BiTE secretion overcomes antigen escape in BCMA targeted CAR T cell therapy for multiple myeloma

Clonoseq MRD negativity at day 90 is a strong predictor for progression free and overall survival after BCMA directed CAR T cell therapy for relapsed multiple myeloma